A cost analysis of outpatient care for patients with Barrett's esophagus in a managed care setting

American Journal of Gastroenterology

Volumn 94, Issue 8, 1999, Pages 2033-2036

  Eloubeidi, Mohamad A ^a,c   Roman, Rick K ^a   Martz, Michael D ^b   Theobald, Karl E ^c   Provenzale, Dawn ^c  

^a Institute for Clinical and Epidemiological Research   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG COST; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; OUTPATIENT CARE; PRIORITY JOURNAL;

AGED; AMBULATORY CARE; BARRETT ESOPHAGUS; COHORT STUDIES; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; DRUG COSTS; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NORTH CAROLINA; REFERRAL AND CONSULTATION;

EID: 0033180394     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.01274.x     Document Type: Article

References (21)

1. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barren's) esophagus. N Engl J Med 1985;313:857-9.
2. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991;20:791-816.
3. Spechler SJ, Goyal RK. Barren's esophagus. N Engl J Med 1986:315:362-71.
4. Winters CJ, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
5. Anonymous. The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract. Guidelines for clinical application. Gastrointest Endosc 1988; 34:18S-20S.
6. Spechler SJ. Endoscopie surveillance for patients with Barrett esophagus: Does the cancer risk justify the practice? Ann Intern Med 1987;106:902-4.
7. Sampliner RE, and the Practice Parameters Committee of the American College of Gastroenterology. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol 1998;93:1028-32.
8. Achkar E, Carey \V. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988:83:291-4.
9. Provenzale D, Kemp JA, Arora S, et al. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994:89:670-80.
10. Durham Veterans Affairs Medical Center Pharmacy and Therapeutics Committee. Drug utilization evaluation (DUE) of proton pump inhibitors. Durham, NC: DVAMC, 1998.
11. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991:265:1287-9.
12. Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA 1993:270: 1320.
13. Spechler SJ. Short and ultrashort Barrett's esophagus-What does it mean? Semin Gastrointest Dis 1997;8:59-67.
14. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996:39:574-9.
15. Levin TR, Schmittdiel JA, Kunz K, et al. Costs of acid related disorders to a health maintenance organization. Am J Med 1997:103:520-8.
16. Segal R, Rüssel WL, Ben-Joseph R, et al. Cost of acid peptic disorders in a managed-care organization. Clin Ther 1996;18: 319-33.
17. Johnson DA, Winters C, Spurling TJ, et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987; 9:23-7.
18. Eloubeidi MA, Provenzale D. Health-related quality of life in patients with Barrett's esophagus and in GERD patients without Barrett's esophagus. Am J Gastroenterol 1998:93:1755 (abstract).
19. Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997:92:582-5.
20. Survey of Medical System Users. Prepared for the Department of Veterans Affairs, Office of the Deputy Assistant Secretary for Planning and Management Analysis. Washington, DC: Arawac Consulting, 1990.
21. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982:96:102-9.